Home » Topics » BioWorld Science, Hematologic

BioWorld Science, Hematologic
RSS

First volunteers dosed with R.W. Johnson's new gpIIb/IIIa antagonist

Aug. 14, 1998

NQ-304, a novel platelet antiaggregatory and antithrombotic agent in early development

Aug. 12, 1998

New antiplatelet agent, PDE III inhibitor, reported by Taiwanese scientists

Aug. 11, 1998

Roberts receives permission to launch Agrylin in Israel

Aug. 10, 1998

Predictors of vascular access site complications during angioplasty with eptifibatide

July 31, 1998

Ibex suspends phase III trial of Neutralase pending further analysis of data

July 30, 1998

BTG offers novel iron complexes for licensing

July 30, 1998

Reduced incidence of death following hirudin/streptokinase therapy for acute myocardial infarction

July 30, 1998

Rights to rhFIX gene for use in gene therapy available from BTG

July 29, 1998

Platelet activity after coronary thrombolysis with reteplase and alteplase

July 29, 1998

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 18, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 16, 2026
Elixiron’s enrupatinib shows upbeat interim phase II AD results
BioWorld
Elixiron Immunotherapeutics Inc. announced positive interim open-label phase II Alzheimer’s disease (AD) study findings of enrupatinib, an oral brain-penetrant...
mRNA flu vaccine can activate broad germinal center response
BioWorld
On the eve of the June 17 Vaccines and Related Biological Products Advisory Committee (VRBPAC) meeting, which will discuss Moderna Inc.’s mRNA-1010, researchers...
GLP-1s need technologies for long-term use
BioWorld
For the long-term impact of GLP-1 therapies in obesity to be realized, they must be paired with data and digital tools. While the drugs are effective, challenges...